TABLE 1.
Predicted versus observed AUC and Cmax in plasma and lung for the 6 drugs at the training and validation doses visualized in Figure 2.
| Drug | Dose (mg/kg) | Train | Val. | Plasma AUC0-t (mg*h/L) | Plasma CMAX (mg/L) | Lung AUC0-t (μg*h/g) | Lung CMAX (μg/g) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Obs. | Pred. | Obs. | Pred. | Obs. | Pred. | Obs. | Pred. | ||||
| INH | 5 | √ | 9.93 | 12.38 (7.27–19.58) | 4.91 | 5.03 (4.11–5.76) | 9.7 | 11.97 (7.63–16.76) | 4.44 | 5.48 (4.48–6.28) | |
| 25 | √ | 58.56 | 54.93 (35.01–76.86) | 22.93 | 25.17 (20.57–28.83) | 63.89 | 59.87 (38.17–83.78) | 25.28 | 27.44 (22.42–31.43) | ||
| RPT | 15 | √ | 503.7 | 562.38 (437.79–654.06) | 16.94 | 16.66 (15.79–17.21) | NA | 714.22 (555.99–830.65) | NA | 21.16 (20.06–21.86) | |
| 20 | √ | 657.84 | 749.79 (583.83–872.07) | 21.94 | 22.21 (21.06–22.95) | NA | 952.24 (741.45–1,107.53) | NA | 28.21 (26.74–29.15) | ||
| PZA | 150 | √ | √ | 346.1 | 358.37 (211.54–557.40) | 161.2 | 121.81 (97.25–141.88) | 262.8 | 231.01 (136.36–359.30) | 93.6 | 78.52 (62.69–91.46) |
| MOX | 100 | √ | 23.58 | 21.09 (11.82–36.96) | 14.18 | 11.80 (7.79–16.74) | NA | 48.73 (27.31–85.38) | NA | 27.26 (18.00–38.66) | |
| 200 | √ | 34.84 | 42.19 (23.64–73.92) | 20.04 | 23.60 (15.58–33.46) | NA | 94.77 (65.16–149) | NA | 54.53 (41.67–72.65) | ||
| BDQ | 25 | √ | √ | 35.9 | 30.83 (16.31–57.08) | 2.72 | 1.58 (0.94–2.49) | 635.9 | 527.56 (279.06–976.65) | 23.3 | 27.07 (16.00–42.54) |
| PRE | 25 | √ | 50.9 | 62.16 (35.63–100.17) | 6 | 6.18 (4.5–7.87) | 139.9 | 170.32 (97.64–274.48) | 17.8 | 16.94 (12.53–21.57) | |
| 100 | √ | 327.6 | 248.61 (142.52–400.70) | 36.81 | 24.74 (18.28–31.49) | NA | 681.19 (390.51–1,097.93) | NA | 67.78 (50.09–88.27) | ||
Median, five and ninety-five-percentile intervals are reported. AUC0-t refers to AUC0-24 for all drugs except INH and PZA for which an AUC0-8 was computed as in the data. Abbreviations: INH - isoniazid; RPT - rifapentine; PZA - pyrazinamide; MOX - moxifloxacin; BDQ - bedaquiline; PRE - pretomanid.